Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 2026 Cantor Global Healthcare Conference
Bo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A live webcast of the presentation will be available by clicking here.
- 2026 Citi Biopharma Back to School Conference
Mr. Cumbo and Dr. Brooks will participate in a fireside chat on Thursday, September 10, 2026, at 3:00 p.m. ET. A live webcast of the presentation will be available by clicking here.
- H.C. Wainwright 28th Annual Global Investment Conference
Mr. Cumbo will participate in a fireside chat on Monday, September 14, 2026, at 1:00 p.m. ET. A live webcast of the presentation will be available by clicking here.
Each fireside chat webcast will also be available on the Events page of the Investors section of the Company website. Webcast replays will be archived for 90 days on the Events page.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com and follow us on LinkedIn at Solid Biosciences and X at @Solid_Bio.
Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Amir Khan
Corporate Affairs Practice
Syneos Health
amir.khan@Syneoshealth.com
(347) 249-0230
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States